Xencor Holds Annual Stockholders Meeting on June 12

Xencor ( (XNCR) ) just unveiled an announcement.

On June 12, 2025, Xencor, Inc. held its Annual Meeting of Stockholders, where 94.68% of the company’s shares were represented. During the meeting, stockholders elected eight directors, ratified KPMG LLP as the independent accounting firm, approved an amendment to increase shares in the Equity Incentive Plan by 3,000,000, and supported the executive compensation plan.

The most recent analyst rating on (XNCR) stock is a Buy with a $38.00 price target. To see the full list of analyst forecasts on Xencor stock, see the XNCR Stock Forecast page.

Spark’s Take on XNCR Stock

According to Spark, TipRanks’ AI Analyst, XNCR is a Neutral.

Xencor’s overall stock score reflects significant financial and valuation challenges. While technical analysis indicates weak momentum, recent corporate events offer a positive outlook, potentially offsetting some risks. The financial performance, however, remains the most critical concern, impacting the overall score heavily.

To see Spark’s full report on XNCR stock, click here.

More about Xencor

Xencor, Inc. operates in the biotechnology industry, focusing on the development of engineered monoclonal antibodies for the treatment of cancer and autoimmune diseases.

Average Trading Volume: 964,334

Technical Sentiment Signal: Sell

Current Market Cap: $677.5M

See more insights into XNCR stock on TipRanks’ Stock Analysis page.